AnalystsGavin Clark-Gartner
Gavin Clark-Gartner's Stock Forecasts

Analyst Ranking
Bottom 7%
#4864 out of 5213 analysts
Average Return
-3.41%
Win Rate
47%18 out of 38
Risk vs Reward
Poor
Good

Gavin Clark-Gartner's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Definium Therapeutics IncDFTX
+135.26%$7.43$17.48
2025-01-27 -
2026-01-27
Buy
Argenx SeARGX
+76.16%$354.13$623.82
2023-12-20 -
2024-12-20
Buy
Argenx SeARGX
+53.92%$596.74$918.50
2024-11-20 -
2025-11-20
Buy
Mirum Pharmaceuticals IncMIRM
+51.63%$59.97$90.93
2025-08-07 -
2026-03-10
Buy
Mirum Pharmaceuticals IncMIRM
+50.04%$39.87$59.82
2024-08-07 -
2025-08-07
Buy

Gavin Clark-Gartner Analyst Color

Get additional color on Gavin Clark-Gartner's coverage of popular stocks

Gavin Clark-Gartner's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Mirum Pharmaceuticals IncMIRM
5Buy$126.00+38.57%Maintains
7 days ago
Abbvie IncABBV
6Buy$228.00+0.44%Maintains
a month ago
Dyne Therapeutics IncDYN
1Buy$36.00+82.00%Maintains
3 months ago
Vera Therapeutics IncVERA
1Buy$97.00+140.99%Maintains
3 months ago
Evommune IncEVMN
1Buy$40.00+66.67%Initiates Coverage On
3 months ago
Forte Biosciences IncFBRX
1Buy$65.00+129.93%Initiates Coverage On
4 months ago
Argenx SeARGX
5Buy$910.00+22.51%Maintains
4 months ago
Jasper Therapeutics IncJSPR
4Buy$14.00+921.90%Maintains
6 months ago
Proqr Therapeutics NvPRQR
1Buy$5.00+177.78%Initiates Coverage On
10 months ago
Definium Therapeutics IncDFTX
1Buy$23.00N/AInitiates Coverage On
a year ago
Cabaletta Bio IncCABA
2Hold$6.00N/ADowngrades
a year ago
Sarepta Therapeutics IncSRPT
9Buy$170.00N/AMaintains
a year ago
Foghorn Therapeutics IncFHTX
1Buy$20.00N/AInitiates Coverage On
2 years ago
Krystal Biotech IncKRYS
1Buy$206.00N/AMaintains
2 years ago
Aclaris Therapeutics IncACRS
1Buy$22.00N/AInitiates Coverage On
2 years ago
C4 Therapeutics IncCCCC
1Buy$10.00N/AMaintains
3 years ago
Inhibrx IncINBX1
1Buy$60.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.